Literature DB >> 3580268

Tumour aneuploidy, prognostic parameters and survival in primary breast cancer.

A A Owainati, R A Robins, C Hinton, I O Ellis, C S Dowle, B Ferry, C W Elston, R W Blamey, R W Baldwin.   

Abstract

Cellular DNA content of primary tumours from 280 patients with operable breast cancer was determined by flow cytometry using nuclei from paraffin sections stained with DAPI, and 199 of these patients were followed for 8-13 years after surgery. Tumours from 67 patients have also been analyzed for their DNA content using single cell suspensions from fresh tumour tissue stained with mithramycin and ethidium bromide, and the results compared with those obtained from paraffin blocks of the same tumours. Overall 60% of the tumours contained cells with abnormal DNA content (DNA-aneuploid populations). Survival and disease free interval were not significantly different in patients with DNA-diploid and DNA-aneuploid tumours when analysed by Mantel's life table method. There was however, an early advantage for patients with DNA-diploid tumours: during the first 30 months after surgery DNA-aneuploidy was associated with higher rate of recurrence and shorter survival. DNA-aneuploidy was strongly related to histological grade. Thus 11/49 (22%) grade I, 60/102 (59%) grade II, and 96/129 (74%) grade III tumours were DNA-aneuploid. Although there was no significant difference in survival of patients with DNA-diploid and DNA-aneuploid tumours overall, there appears to be an unexpected association between DNA-aneuploidy and better survival in grade II patients (P less than 0.01); a similar trend was observed for grade I patients. Although the proportion of DNA-aneuploid tumours was similar in oestrogen receptor positive and negative tumours, DNA-aneuploidy was associated with lower levels of oestrogen receptors in comparison to DNA-diploid tumours. Comparison between the modal DNA values of fresh and paraffin embedded samples showed high rate of comparability (64/67, P less than 0.0001).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580268      PMCID: PMC2001704          DOI: 10.1038/bjc.1987.88

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  DNA content and survival in mammary carcinoma.

Authors:  G U Auer; T O Caspersson; A S Wallgren
Journal:  Anal Quant Cytol       Date:  1980-09

2.  Steroid receptors in early breast cancer: value in prognosis.

Authors:  R I Nicholson; F C Campbell; R W Blamey; C W Elston; D George; K Griffiths
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

3.  Modal deoxyribonucleic acid value and survival in carcinoma of the breast.

Authors:  N B Atkin
Journal:  Br Med J       Date:  1972-01-29

4.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

5.  Flow cytometry of breast carcinoma: I. Relation of DNA ploidy level to histology and estrogen receptor.

Authors:  W Olszewski; Z Darzynkiewicz; P P Rosen; M K Schwartz; M R Melamed
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

6.  Nuclear feulgen DNA content and nuclear size in human breast carcinoma.

Authors:  S D Fosså; P F Marton; O S Knudsen; O Kaalhus; O Børmer; S Vaage
Journal:  Hum Pathol       Date:  1982-07       Impact factor: 3.466

7.  The influence of age on the DNA ploidy levels of breast tumours.

Authors:  I W Taylor; E A Musgrove; M L Friedlander; M S Foo; D W Hedley
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

8.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

9.  Prognostic significance of modal DNA value and other factors in malignant tumours, based on 1465 cases.

Authors:  N B Atkin; R Kay
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

10.  The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects.

Authors:  C W Elston; G A Gresham; G S Rao; T Zebro; J L Haybittle; J Houghton; G Kearney
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

View more
  20 in total

Review 1.  Aneuploidy as a prognostic factor in breast cancer.

Authors:  A von Rosen
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells.

Authors:  Jewel Daniel; Jonathan Coulter; Ju-Hyung Woo; Kathleen Wilsbach; Edward Gabrielson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

4.  Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.

Authors:  E B Austin; R A Robins; L G Durrant; M R Price; R W Baldwin
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

Review 5.  The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells.

Authors:  M Zanetti; J J Rodvold; N R Mahadevan
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

6.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

7.  DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases.

Authors:  G E Feichter; M Kaufmann; A Müller; D Haag; R Eckhardt; K Goerttler
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

8.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

9.  Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.

Authors:  S A Brooks; A J Leathem; R S Camplejohn; W Gregory
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Paragangliomas: neuroendocrine features and cytometric DNA distribution patterns. A clinico-pathological study of 22 cases.

Authors:  R Jovanovic; G W Hacker; U G Falkmer; S Falkmer; L Mendel; A H Graf; A Höög; V Kanjuh; C Silfverswärd; L Grimelius
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.